"Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin‐pump‐treated patients with type 1 diabetes: The Lira Pump trial—a randomized, double‐blinded, placebo‐controlled trial"

LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin‐pump‐treated patients with type 1 diabetes: The Lira Pump trial—a randomized, double‐blinded, placebo‐controlled trial

To investigate the efficacy of adding the glucagon‐like peptide‐1 receptor agonist liraglutide to continuous subcutaneous insulin infusion (CSII) in overweight or obese persons with type 1 diabetes and non‐optimal glycaemic… Click to show full abstract

Keywords: reduces hyperglycaemia; insulin; trial; liraglutide reduces; type diabetes; hyperglycaemia body

Journal Title: Diabetes
Year Published: 2019

Link to full text (if available)

Share on Social Media: Sign Up to like & get
recommendations!
0

LAUSR

You are not signed in:

Sign Up!

Related content

More Information News Social Media Video Recommended